Polish-Italian-Hungarian RAndomized ThrombEctomy Trial
Launched by JAGIELLONIAN UNIVERSITY · Sep 14, 2006
Trial Information
Current as of June 07, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ST elevation acute myocardial infarction within 6 hours since pain onset, with 2 mm ST segment elevation in two lead
- • Minimum 3 mm ST segment elevation in one leads
- • Vessel reference diameter \> 2.5 mm
- • When vessel reference diameter ≥ 4,0 mm than additional distal protection device (filter) is needed during stent implantation
- Exclusion Criteria:
- • Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA, thienopirydins or GP IIb/IIIa inhibitors
- • Active bleeding or coagutopathy
- • Prior CABG or PCI
- • Known ejection fraction EF \<35%
- • Cardiogenic shock /SBP \< 90 mmHg, IABP and/or catheloamins usage/
- • LBBB, pacemaker rhythm
- • Severe calcifications
- • Previous Myocardial infarction
- • Stroke history
- • Patient directly after reanimation
- • Known thrombocytopenia- platelets \< 100 000
- • Pregnancy
- • Cancer disease
- • No future patient cooperation expected
- • Patient's taking part in the other clinical trials
- • Fibrynolisis directly administered before PCI
- • Renal insufficiency (creatynine \> 220 µmol/ml), hemodialysis
- • Contraindications to PCI (contrast allergy, no possibility to stent implantation) ASA, thienopirydins or GP IIb/IIIa inhibitors
- • Active bleeding or coagutopathy
- • Prior CABG or PCI
- • Known ejection fraction EF \<35%
- • Cardiogenic shock /SBP \< 90 mmHg, IABP and/or catheloamins usage/
- • LBBB, pacemaker rhythm
- • Severe calcifications
- • Previous Myocardial infarction
- • Stroke history
- • Patient directly after reanimation
- • Known thrombocytopenia- platelets \< 100 000
- • Pregnancy
- • Cancer disease
- • No future patient cooperation expected
- • Patient's taking part in the other clinical trials
- • Fibrynolisis directly administered before PCI
- • Renal insufficiency (creatynine \> 220 µmol/ml), hemodialysis
- • Liver insufficiency
About Jagiellonian University
Jagiellonian University, one of the oldest and most prestigious institutions of higher education in Poland, is a leading sponsor of clinical trials dedicated to advancing medical research and healthcare innovation. With a strong commitment to scientific excellence, the university leverages its extensive resources, multidisciplinary expertise, and collaborative network to conduct rigorous clinical studies that contribute to the development of new therapies and treatment strategies. Jagiellonian University emphasizes ethical research practices and strives to enhance patient outcomes through evidence-based findings, making significant contributions to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pecs, , Hungary
Genova, , Italy
Rome, , Italy
Katowice, , Poland
Krakow, , Poland
Nowy Sacz, , Poland
Przemyśl, , Poland
Warszawa, , Poland
Zabrze, , Poland
Patients applied
Trial Officials
Dariusz Dudek, MD
Principal Investigator
Jagiellonian University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials